The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

HealthDay News — Many people with cancer get directly involved in prior authorization (PA), often facing substantial time burdens, according to a study presented at the 2025 American Society of ...

HealthDay News — Pickleball-related eye injuries increased from 2021 to 2024 as the sport became more popular, according to a study published online October 16 in JAMA Ophthalmology.

Overall and event-free survival of 100 and 95%, respectively, seen with autologous CD34+ hematopoietic stem-cell lentiviral gene therapy.

Both low and high increases in use were negatively but weakly associated with adolescent cognitive performance 2 years later.

Nearly 700 medicines used in the US to treat common conditions contain at least one chemical sourced only in China.

Jessie J. Goldsmith, from University of Melbourne in Australia, and colleagues conducted a systematic literature review to estimate the increase in protection associated with the second dose of ...

Association between continued smoking and all-cause mortality also seen in patients with advanced-stage cancer.

BPL-003 is a novel, nasal spray formulation of mebufotenin benzoate designed to deliver rapid and durable antidepressant effects from a single dose.